Metoject Pen

Methotrexate, the active ingredient in Metoject Pen, is an antimetabolite presented as a pre‑filled pen injection for subcutaneous use. It treats autoimmune conditions such as rheumatoid arthritis and psoriasis, as well as certain cancers, in adult and pediatric patients.

GNH USA supplies Metoject Pen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is employed across several disease families, primarily autoimmune and oncologic disorders.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Crohn's disease: helps achieve and maintain remission of intestinal inflammation. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation as part of chemotherapy protocols.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mild oral ulceration. - Transient elevation of liver enzymes. - Low white blood cell count (leukopenia). - Mild hair thinning.

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Significant bone marrow suppression leading to pancytopenia. - Renal impairment or acute kidney injury. - Severe cutaneous reactions such as Stevens‑Johnson syndrome. - Teratogenic effects causing fetal malformations.

Methotrexate requires careful monitoring and patient education to minimize risks.

- Baseline testing: obtain liver function, renal function, and complete blood count before initiating therapy. - Monitoring: repeat laboratory assessments regularly to detect toxicity early. - Contraindications: avoid use in pregnancy due to known teratogenicity. - Drug holidays: consider temporary discontinuation before major surgery or invasive procedures. - Patient counseling: advise on avoiding alcohol and informing about signs of infection or liver injury. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can alter its efficacy or toxicity.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise methotrexate plasma levels. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely): - Penicillins and other antibiotics: may affect renal clearance. - Live vaccines: risk of severe infection due to immunosuppression. - Folate supplements: can reduce efficacy but are often used to mitigate side effects; adjust dose under medical supervision.